<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en">
<!--CytoSwitch project Webpage-->

<head>
	<title>CytoSwitch</title>
	<meta http-equiv="content-type" content="text/html; charset=utf-8" />
	<link rel="stylesheet" type="text/css" media="screen" href="./files/style.css" />
	<link rel="apple-touch-icon" sizes="57x57" href="./files/favicons/apple-touch-icon-57x57.png"/>
	<link rel="apple-touch-icon" sizes="60x60" href="./files/favicons/apple-touch-icon-60x60.png"/>
	<link rel="apple-touch-icon" sizes="72x72" href="./files/favicons/apple-touch-icon-72x72.png"/>
	<link rel="apple-touch-icon" sizes="76x76" href="./files/favicons/apple-touch-icon-76x76.png"/>
	<link rel="apple-touch-icon" sizes="114x114" href="./files/favicons/apple-touch-icon-114x114.png"/>
	<link rel="icon" type="image/png" href="./files/favicons/favicon-32x32.png" sizes="32x32"/>
	<link rel="icon" type="image/png" href="./files/favicons/favicon-96x96.png" sizes="96x96"/>
	<link rel="icon" type="image/png" href="./files/favicons/favicon-16x16.png" sizes="16x16"/>
	<link rel="manifest" href="./files/favicons/manifest.json"/>
	<link rel="mask-icon" href="./files/favicons/safari-pinned-tab.svg" color="#5bbad5"/>
	<link rel="shortcut icon" href="./files/favicons/favicon.ico"/>
	<meta name="msapplication-TileColor" content="#da532c"/>
	<meta name="msapplication-config" content="./files/favicons/browserconfig.xml"/>
	<meta name="theme-color" content="#ffffff"/>
	<meta name="author" content="Oliver Thorn-Seshold" />
	<meta name="description" content="CytoSwitch website" /> 
	<meta name="keywords" content="Cytoswitch Photostatin Photostatins Photopharmacology Probes Chemotherapy BioVaria MBPW Cyto Switch Oliver Torvald Thorn-Seshold Chimie Chemie Chemistry Photo-Can PhotoCan LMU Munich Munchen"/>
</head>

<body>

<!-- Header-->
<div id="header">
	<img id="logoleft" src="./files/cytoswitchlogo.png" alt="CytoSwitch logo" />
	<h2>Cyto<i>Switch</i> Project</h2>
</div><!-- End of Header div -->

<!-- Main page-->
<div id="page">

<!-- Left Menu Column-->
<div id="leftcolumn"> 
	<ul id="verticalmenu">
		<li><em>Home</em></li>
		<li><a href="news.html" title="News">News</a></li>
<!--		<li>Technology</li> --><!-- <a href="tech.htm" title="Technology">Technology</a> -->
<!--		<li>Contact</li>  --><!-- <a href="contact.htm" title="Contact">Contact</a> -->
	</ul>
</div><!-- End of Left Menu Column -->
 
<!-- Main text area -->  
<div id="maincolumn">

<h4><big>Cyto<i>Switch</i> is a Munich-based biotech project to develop targeted chemotherapeutics and smart probes.</big></h4>

<p>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cancer chemotherapeutics cause severe side-effects in healthy tissues - like immunosuppression in bone marrow, peripheral nerve toxicity, GI tract toxicity etc. These toxicities often limit the tolerable doses of chemotherapy drugs down to levels that are just not effective for curing cancers.<br /><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We developed a <i>targeted</i> antimitotic drug called Photostatin (PST), recently published in the prestigious scientific journal <b><em><a href="http://dx.doi.org/10.1016/j.cell.2015.06.049" title="Photostatins in Cell, 2015">Cell</a></em></b>. PST is a unique drug, because it can be targeted to specific cells while avoiding all others, just by using light. Our aim is to use PST as a chemotherapeutic that targets cancer tumours while <em>avoiding the healthy tissues</em>. Because of this targeting, PST could be used at much higher dosage than current drugs, without causing increased side effects: or, equivalently, PST could offer much reduced side-effects compared to current chemotherapies, when used at similar dosage.<br /><br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;That means:<br />
&#8226; (1) PST could tackle refractory tumours, which do not respond to tolerable doses of current drugs; and<br />
&#8226; (2) PST could treat weaker patients, who cannot tolerate the "normal" side-effects of current treatments. <br />
<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cyto<i>Switch</i> will take PST towards clinical trials as tumour-targeted chemotherapeutics. In parallel we will commercialise them for research use.</p>
<br />

<h4>Cyto<i>Switch</i> Timeline</h4>

<p>Cyto<i>Switch</i> is currently in the pre-startup phase.<!-- Sign-up to our newsletter to be up-to-date with our latest developments (forthcoming).--></p>

</div><!-- End of Main Column -->

<p class="clear"></p>
<br /><br /><br />
</div><!-- End of Main Page Div -->

<!-- Footer notes and links -->   
<div id="footer"> 
<p><small>last updated 2016-02</small><!-- <small>*We take no responsibility for news articles written by third parties; please consult our peer-reviewed scientific publications for fact-checking.</small> --></p>
</div><!-- end of footer -->

</body>
</html>